GlaxoSmithKline Q4 consolidated net profit declines 6% to Rs 138 cr
The company had posted a net profit of Rs 146.81 crore for the same period previous fiscal, GlaxoSmithKline Pharmaceuticals said in a BSE filing.
 "GlaxoSmithKline Q4 consolidated net profit declines 6% to Rs 138 cr")
premium
Drug firm GlaxoSmithKline Pharmaceuticals on Monday reported a 5.95 per cent decline in its consolidated net profit to Rs 138.07 crore for the fourth quarter ended March 31, 2020.
The company had posted a net profit of Rs 146.81 crore for the same period previous fiscal, GlaxoSmithKline Pharmaceuticals said in a BSE filing.
Consolidated revenue from operations stood at Rs 775.80 crore for the quarter under consideration. It was Rs 750.81 crore in the same period a year ago.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%